IMO-2125: Preliminary Phase I/II data

Preliminary data from 6 evaluable patients with metastatic melanoma who failed prior PD-1 therapy in the Phase I portion of the open-label, U.S. Phase I/II IMO-2125-204 trial showed that 4 and 8 mg/k...